Saturday, October 31, 2026

CDW Corporation Stock Went Down By Over 13% So Far Today

CDW Corporation Stock Went Down By Over 13% So Far Today

(VIANEWS) - Shares of CDW Corporation (NASDAQ: CDW) dropped by a staggering 13.52% to $164.56 at 11:22 EST on Wednesday, after two consecutive sessions in a row of gains. NASDAQ is falling 0.56% to $12,085.91, following the last session's downward trend. This seems, up until now, a somewhat bearish trend trading session today.

CDW Corporation's last close was $190.29, 11.49% below its 52-week high of $215.00.

About CDW Corporation

CDW Corporation provides information technology (IT) solutions in the United States, the United Kingdom, and Canada. It operates through three segments: Corporate, Small Business, and Public. The company offers discrete hardware and software products and services, as well as integrated IT solutions, including on-premise, hybrid, and cloud capabilities across hybrid infrastructure, digital experience, and security. Its hardware products comprise notebooks/mobile devices, network communications, desktop computers, video monitors, enterprise and data storage, and others; and software products consists of application suites, security, virtualization, operating systems, and network management. The company also provides advisory and design, software development, implementation, managed, professional, configuration, partner, and telecom services, as well as warranties; delivers and manages mission critical software, systems, and network solutions; and implementation and installation, and repair services to its customers through various third-party service providers. It serves government, education, and healthcare customers; and small, medium, and large business customers. CDW Corporation was founded in 1984 and is headquartered in Vernon Hills, Illinois.

Earnings Per Share

As for profitability, CDW Corporation has a trailing twelve months EPS of $8.13.

PE Ratio

CDW Corporation has a trailing twelve months price to earnings ratio of 20.24. Meaning, the purchaser of the share is investing $20.24 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 96.54%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Feb 22, 2023, the estimated forward annual dividend rate is 2.36 and the estimated forward annual dividend yield is 1.26%.

Growth Estimates Quarters

The company's growth estimates for the ongoing quarter and the next is 3.2% and 3.2%, respectively.

Sales Growth

CDW Corporation's sales growth is negative 6.5% for the present quarter and negative 3.1% for the next.

Volatility

CDW Corporation's last week, last month's, and last quarter's current intraday variation average was 0.30%, 0.12%, and 1.21%.

CDW Corporation's highest amplitude of average volatility was 0.90% (last week), 1.12% (last month), and 1.21% (last quarter).

More news about CDW Corporation (CDW).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com